Related Experiment Video
Updated: Jan 7, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Antibiotic Combinations in Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic
Miao Duan1,2,3, Teng Teng1,2,3, Qingzhou Kong1,2,3
1Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, China.
Background And Aims:
The rising antibiotic resistance of Helicobacter pylori has led to variability in efficacy of bismuth-containing quadruple therapy (BcQT). This network meta-analysis (NMA) aimed to compare the efficacy of antibiotic combinations in first-line BcQT.
Methods:
Following PRISMA guidelines with PROSPERO registration (CRD420251005598), we systematically searched PubMed, Embase, Web of Science, and Cochrane Library for randomized controlled trials (RCTs) published between January 1, 2005 and March 21, 2025. Eligible studies were selected by predefined criteria. Dichotomous outcomes included H. pylori eradication rates, adverse events, and compliance, analyzed as odds ratios (ORs) with 95% credible intervals (95% CrI) or 95% confidence intervals (95% CI). Treatments were ranked via surface under the cumulative ranking curve (SUCRA).
Results:
This NMA included 25 RCTs (n = 7624) evaluating 19 regimens. Amoxicillin-metronidazole ranked highest globally (SUCRA = 0.866) in intention-to-treat analyses and in Asia (SUCRA = 0.851), particularly during 2016-2025 (SUCRA = 0.859; OR = 3.43, 95% CrI 1.17-10.05). Metronidazole-tetracycline was optimal in Europe (SUCRA = 0.969; OR = 2.13, 95% CrI 1.15-3.95), amoxicillin-minocycline in China (SUCRA = 0.733). Notably, regimens including levofloxacin or clarithromycin significantly decreased eradication rates in China (OR = 1.32; 95% CI 1.04-1.66; p = 0.02). Amoxicillin-furazolidone had the poorest adverse events (SUCRA = 0.792). Compliance was highest with amoxicillin-moxifloxacin (SUCRA = 0.878).
Conclusion:
Superior eradication was achieved with BcQT by utilizing dual low-resistance antibiotics per local surveillance data. Amoxicillin-metronidazole may represent optimal regimens for primary H. pylori eradication efficacy in BcQT. Substantial efficacy variation in antibiotic combinations necessitates tailored treatment guided by antibiotic resistance surveillance.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.